SCHEMBL8914972

SCHEMBL8914972

Cc1ccccc1NC(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.69
TAS1R3 Q7RTX0 2/20 0.68
TAS1R1 Q7RTX1 2/20 0.68
TAS1R2 Q8TE23 2/20 0.68
NPC1 O15118 5/20 0.66
RAB9A P51151 5/20 0.66
POLB P06746 3/20 0.63
HPGD P15428 1/20 0.63
TP53 P04637 2/20 0.60
THRB P10828 1/20 0.60
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
SMN1; SMN2 Q16637 1/20 0.58
MAPT P10636 3/20 0.57
KDM4E B2RXH2 2/20 0.57
PKM P14618 1/20 0.57
ALDH1A1 P00352 2/20 0.56
GAA P10253 1/20 0.56
HTT P42858 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17921645 0.87 TAS1R3 (0.63) LMNATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL11313791 0.87 LMNA (0.64) LMNATAS1R3TAS1R1TAS1R2NPC1
Hydrochloric Acid SCHEMBL16539869 0.85 TAS1R3 (0.61) LMNATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL28090884 0.84 MEN1 (0.60) LMNATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL28090633 0.84 TAS1R3 (0.60) LMNATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL7030759 0.84 LMNA (0.55) LMNATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL7037306 0.84 LMNA (0.55) LMNATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL7030757 0.84 LMNA (0.55) LMNATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL16539576 0.83 TAS1R3 (0.59) LMNATAS1R3TAS1R1TAS1R2NPC1
SCHEMBL9055150 0.83 HPGD (0.89) LMNATAS1R3TAS1R1TAS1R2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238750-A1 AROMATIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2012-09-20 US disclosed
US-8236826-B2 Diarylether derivatives as antitumor agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-08-07 US disclosed
US-8236826-B2 Diarylether derivatives as antitumor agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-08-07 US disclosed
US-8188277-B2 Aromatic compounds for suppressing the generation of collagen OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-05-29 US disclosed
US-8188277-B2 Aromatic compounds for suppressing the generation of collagen OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-05-29 US disclosed
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 US disclosed
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed
WO-2007066784-A2 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238750-A1 AROMATIC COMPOUND CBR1, CBR3, CYP1A1 LMNA 2721/4885TAS1R3 686/4885TAS1R1 298/4885
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS ROS1, CBR1, CBR3 LMNA 4340/4885TAS1R3 2478/4885TAS1R1 1489/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 LMNA 1091/4885TAS1R3 1004/4885TAS1R1 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.